NasdaqGS - Nasdaq Real Time Price ? USD Madrigal Pharmaceuticals, Inc. (MDGL) Follow Compare 216.17 +0.74 (+0.34%) At close: October 15 at 4:00 PM EDT 218.23 +2.06 (+0.95%) Pre-Market: 5:29 AM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations High Growth Tech Stocks To Watch In October 2024 Over the last 7 days, the United States market has remained flat but is up 30% over the past year with earnings forecast to grow by 15% annually. In this environment, identifying high growth tech stocks involves looking at companies that not only show strong potential for revenue expansion but also align well with current market conditions. Simply Wall St. ? 6 days ago MDGL +0.34% CORZ CORZR Madrigal Pharmaceuticals to Participate in the?H.C. Wainwright & Co. 8th Annual MASH Investor Conference CONSHOHOCKEN, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced the company will participate in a fireside chat at the H.C. Wainwright 8th Annual MASH Virtual Investor Conference at 2:00 P.M. ET on Monday, Oct. 7, 2024. The fireside chat will be webcast live and may be accessed here or by visiting Madrigal’s website’s Investor Relations Events page. A replay of the webcast will be available after the event. About Madrigal Pharmaceuticals Madriga GlobeNewswire ? 14 days ago MDGL +0.34% Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development CONSHOHOCKEN, Pa., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH), today announced the appointment of Michael R. Charlton, M.B.B.S., F.R.C.P., as Senior Vice President, Clinical Development, effective October 1, 2024. Becky Taub, M.D., Chief Medical Officer and President of Research & Development of GlobeNewswire ? 15 days ago MDGL +0.34% Madrigal Pharmaceuticals Announces Publication of Positive Health-Related Quality of Life Results from the Phase 3 MAESTRO-NASH Trial of Rezdiffra? (resmetirom) Patients with MASH/NASH treated with Rezdiffra experienced clinically meaningful and statistically significant improvements in emotional well-being and health distressStudy results underscore the positive tolerability profile of Rezdiffra CONSHOHOCKEN, Pa., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MA GlobeNewswire ? 16 days ago MDGL +0.34% Is Madrigal Pharmaceuticals, Inc. (MDGL) the Best Guru Stock To Buy Now? We recently compiled a list of the 10 Best Guru Stocks To Buy Now. In this article, we will have a look at where Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) ranks among the best guru stocks to buy now. Due to the plethora of investment options such as equities, bonds, and mutual funds that are available today, […] Insider Monkey ? 21 days ago MDGL +0.34% ^GSPC Exploring 3 High Growth Tech Stocks in the United States Over the last 7 days, the market has dropped 3.4%, but over the longer term, it has risen by 20% in the last year with earnings forecasted to grow by 15% annually. In this dynamic environment, identifying high growth tech stocks that can capitalize on these trends is crucial for investors seeking robust returns. Simply Wall St. ? last month MDGL +0.34% MAX ADMA Madrigal Pharmaceuticals, Inc. to Participate in the?Morgan Stanley 22nd Annual Global Healthcare Conference CONSHOHOCKEN, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, 2024 at 10:45 A.M. ET. The presentation will be webcast live and may be accessed here or by visiting Madrigal’s Investor Relations Events page. A replay of the webcast will be available after the event. About Madrigal PharmaceuticalsMadrigal Pharmaceuticals, Inc GlobeNewswire ? last month MDGL +0.34% Is Madrigal Pharmaceuticals Stock a Buy? The biotech could be worth a lot more in 10 years. Motley Fool ? last month MDGL +0.34% John Paulson's Strategic Exits and Key Investments in Q2 2024: Spotlight on Newmark Group Inc Insights into the Investment Shifts of a Hedge Fund Titan GuruFocus.com ? 2 months ago NMRK MDGL +0.34% This 1 Setback for Novo Nordisk Is Bullish for Madrigal Pharmaceuticals Stock One player's minor pain is another's moderate gain. Motley Fool ? 2 months ago MDGL +0.34% NVO Madrigal plans to solidify Rezdiffra’s position in MASH despite start being slower than expected Rezdiffra is now positioned as the first-line treatment for MASH in the US after its FDA approval. Pharmaceutical Technology ? 2 months ago GLDAF MDGL +0.34% Q2 2024 Madrigal Pharmaceuticals Inc Earnings Call Q2 2024 Madrigal Pharmaceuticals Inc Earnings Call Thomson Reuters StreetEvents ? 2 months ago MDGL +0.34% Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains' Acadia Pharmaceuticals led a biotech stock sell-off Wednesday after revenue from its Rett syndrome treatment missed expectations. Investor's Business Daily ? 2 months ago ACAD MDGL +0.34% ITCI +1.18% Madrigal (MDGL) Tops on Q2 Earnings, NASH Drug Drives Top Line Madrigal (MDGL) posts better than expected second-quarter numbers. It adds nearly $15 million from sales of the first-ever NASH drug Rezdiffra, which is encouraging for a drug launched in April 2024. Zacks ? 2 months ago MDGL +0.34% TRDA HALO Madrigal: Q2 Earnings Snapshot WEST CONSHOHOCKEN, Pa. AP) — Madrigal Pharmaceuticals Inc. MDGL) on Wednesday reported a loss of $152 million in its second quarter. Associated Press Finance ? 2 months ago MDGL +0.34% Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates Second-quarter 2024 net sales of $14.6 million Rezdiffra? (resmetirom) coverage in place for more than 50 percent of commercial lives; less than 5 percent of Rezdiffra-covered lives require biopsyExpert guidelines recommend Rezdiffra as first-line therapy for patients with F2/F3 NASH/MASHPlans to directly commercialize resmetirom in Europe following EMA decision expected mid-year 2025Reports cash, cash equivalents, restricted cash and marketable securities of $1.1 billion at June 30, 2024Company GlobeNewswire ? 2 months ago MDGL +0.34% Madrigal’s MASH drug launch gets off to a fast start U.S. sales of the medicine, Rezdiffra, were more than triple analysts’ expectations, encouraging Madrigal to market it in Europe without a partner. BioPharma Dive ? 2 months ago MDGL +0.34% Is It Too Late to Buy Madrigal Pharmaceuticals Stock? Will being the first to its market ensure that its future is bright? Motley Fool ? 2 months ago MDGL +0.34% Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel CONSHOHOCKEN, Pa., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced the appointment of Shannon Kelley as General Counsel, effective August 5, 2024. Bill Sibold, Chief Executive Officer of Madrigal, stated, “Shannon is an outstanding leader who brings a wealth of expertise to her new role as General Counsel. She joined the Madrigal team in 20 GlobeNewswire ? 2 months ago MDGL +0.34% Top Growth Stocks With High Insider Ownership In US For August 2024 The U.S. stock market has experienced significant volatility recently, with major indexes like the Dow Jones, S&P 500, and Nasdaq Composite seeing sharp declines amid a chip stock selloff and economic concerns. As investors navigate these turbulent times, growth companies with high insider ownership can offer unique advantages due to the confidence insiders have in their own businesses. Simply Wall St. ? 2 months ago BCAL MDGL +0.34% ULCC Performance Overview Trailing total returns as of 10/15/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return MDGL S&P 500 YTD -6.57% +21.92% 1-Year +54.00% +34.37% 3-Year +158.79% +31.03%
